To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Niacin; Niacinamide; Nicotinic Acids; Simvastatin

Criteria

Inclusion Criteria:

• Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL

• Patient willing to be on a low-cholesterol diet

Exclusion Criteria:

• Pregnant or lactating women or intending to become pregnant

• Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet

• Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin

• Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an unacceptable risk